Understand the source comparison
IGF-1 LR3 Blood Work Labs Check Before After: Comparison
This table outlines the key blood work markers to test before starting IGF-1 LR3, the expected changes during administration, and what those changes mean for protocol adjustments. Serum IGF-1 115–307 ng/mL (adult males) May rise 30–60% if receptors are respons
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table outlines the key blood work markers to test before starting IGF-1 LR3, the expected changes during administration, and what those changes mean for protocol adjustments.
- Serum IGF-1
- 115–307 ng/mL (adult males)
- May rise 30–60% if receptors are responsive
- Measures receptor saturation and analog bioavailability
- Stable or declining levels after week 4 suggest receptor downregulation. Consider cycling off
- Fasting Glucose
- <100 mg/dL
- May drop 10–18 mg/dL with sustained use
- Tracks insulin sensitivity and hypoglycemia risk
- Readings below 70 mg/dL require carbohydrate timing adjustments to prevent symptomatic hypoglycemia
- HbA1c
- <5.7%
- Should remain stable or decrease slightly
- 90-day glucose average. Slower to respond than fasting glucose
- Declining HbA1c confirms improved glucose handling; rising HbA1c suggests insulin resistance worsening
- ALT (Alanine Aminotransferase)
- 7–56 U/L
- Should stay stable; elevations above 80 U/L signal hepatic stress
- Liver enzyme indicating hepatocyte damage or metabolic overload
- Sustained elevation above 80 U/L warrants dose reduction or washout period
- AST (Aspartate Aminotransferase)
- 10–40 U/L
- Should remain stable unless liver stress occurs
- Less liver-specific than ALT but corroborates hepatic function
- AST rising faster than ALT may indicate muscle breakdown rather than liver stress